Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC combined with surufatinib and tislelizumab for pancreatic cancer with liver metastasis
ChiCTR2400092323Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and tislelizumab in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Tongji Hospital. Primary endpoint: Objective response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
surufatinibtislelizumab
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400092323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092323.